Shah Rahimian

Statistics

Publications

Citations

197

H-Index

Active since

2018

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Idera Pharmaceuticals (United States)

Roswell Park Comprehensive Cancer Center

University of Arizona

First Affiliated Hospital Zhejiang University

Shah Rahimian is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, cancer immunotherapy, and checkpoint inhibitor therapy.

Publications per year

2018–2025

Publications

Oncolytic virus VG161 in refractory hepatocellular carcinoma

Yinan Shen, Xueli Bai, Qi Zhang et al. · Nature · 2025 · 74 citations

Medicine, Molecular Biology, Oncology +14

Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma

Cara Haymaker, Daniel H. Johnson, Ravi Murthy et al. · Cancer Discovery · 2021 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

Adi Diab, Shah Rahimian, Cara Haymaker et al. · Journal of Clinical Oncology · 2018 · 23 citations

Life Sciences, Immunology, Oncology +17

Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101)

Hani M. Babiker, Vivek Subbiah, Orla Maguire et al. · Cancer Research · 2019 · 11 citations

Life Sciences, Immunology, Pharmacology +17

Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors

Hani M. Babiker, Vivek Subbiah, Asim Ali et al. · Cancer Research · 2020 · 10 citations

Medicine, Immunology, Oncology +15

1–5 of 6